Phase 1, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety of Intravenous APL-2 in Healthy Volunteers
Latest Information Update: 16 Jul 2019
At a glance
- Drugs Pegcetacoplan (Primary)
- Indications Ischaemia; Paroxysmal nocturnal haemoglobinuria; Wet age-related macular degeneration
- Focus Adverse reactions
- 10 Jan 2017 Status changed from not yet recruiting to completed.
- 30 Jun 2016 New trial record